FOXD1 mutations are related to repeated implantation failure, intra-uterine growth restriction and preeclampsia.

BACKGROUND: Human reproductive disorders consist of frequently occurring dysfunctions including a broad range of phenotypes affecting fertility and women's health during pregnancy. Several female-related diseases have been associated with hypofertility/infertility phenotypes, such as recurrent pregnancy loss (RPL). Other occurring diseases may be life-threatening for the mother and foetus, such as preeclampsia (PE) and intra-uterine growth restriction (IUGR). FOXD1 was defined as a major molecule involved in embryo implantation in mice and humans by regulating endometrial/placental genes. FOXD1 mutations in human species have been functionally linked to RPL's origin. METHODS: FOXD1 gene mutation screening, in 158 patients affected by PE, IUGR, RPL and repeated implantation failure (RIF), by direct sequencing and bioinformatics analysis. Plasmid constructs including FOXD1 mutations were used to perform in vitro gene reporter assays. RESULTS: Nine non-synonymous sequence variants were identified. Functional experiments revealed that p.His267Tyr and p.Arg57del led to disturbances of promoter transcriptional activity (C3 and PlGF genes). The FOXD1 p.Ala356Gly and p.Ile364Met deleterious mutations (previously found in RPL patients) have been identified in the present work in women suffering PE and IUGR. CONCLUSIONS: Our results argue in favour of FOXD1 mutations' central role in RPL, RIF, IUGR and PE pathogenesis via C3 and PlGF regulation and they describe, for the first time, a functional link between FOXD1 and implantation/placental diseases. FOXD1 could therefore be used in clinical environments as a molecular biomarker for these diseases in the near future.

Use of gadolinium for hysterosalpingography in iodine allergic women: a case-control study.

OBJECTIVE: To examine the performance of gadolinium in iodine-sensitive women undergoing hysterosalpingography. DESIGN: Case-control study. SETTING: Odessa Regional Hospital, Texas. PATIENT(S): Seven women, three with no allergies to iodinated contrast medium (controls) and four with known allergies. INTERVENTION(S): Use of gadolinium in women with known allergies to iodinated contrast medium. MAIN OUTCOME MEASURE(S): How does gadolinium compare as a diagnostic tool in hysterosalpingogram versus iodinated contrast medium? RESULT(S): The images of the uterus and unobstructed fallopian tubes produced by gadolinium appear to yield equally diagnostic results compared with images produced by iodinated contrast medium. CONCLUSION(S): It appears that hysterosalpingogram with gadolinium is a viable option for patients that are allergic to iodinated contrast medium.

[Diarrhoea-causing agents in children aged less than five in Tunja, Colombia]. / Agentes causantes de diarrea en niños menores de 5 años en Tunja, Colombia.

OBJECTIVES: Determining the prevalence and type of infectious ADD-causing agents in a sample of children aged less than five who consulted the IPS in Tunja during 2004. MATERIAL AND METHODS: A cross-sectional study was designed. Data was obtained by surveying 129 children younger than 5 suffering from ADD. Samples of faeces were obtained following outpatient consultation at San Rafael Hospital and SaludCoop's clinic in Tunja. RESULTS: Rotavirus was found in 48.1% of cases, Shigella in 0.8%, E. coli in 13.9%, Campylobacter in 2.3%, Giardia lamblia in 12.4% and E. hitolytica in 7%. The causative agent could not be identified in 15.5% of cases. The statistical association grew with age for Rotavirus (p < 0.01), E. coli (p < 0.05) and campylobacter (p < 0.001). CONCLUSION: Rotavirus is the major causative agent of ADD in children younger than one year and, generally, in children aged less than five. The prevalence found was similar to data reported in studies carried out in Facatatativá, Bogotá, Santander, Manizales and the Chocó in Colombia and studies carried out in Venezuela, Peru and Mexico.

Agentes causantes de diarrea en niños menores de 5 años en Tunja, Colombia / Diarrhoea-causing agents in children aged less than five in Tunja, Colombia

Objetivos: Determinar la prevalencia y tipo de agentes infecciosos causantes de EDA en una muestra de niños menores de 5 años que consultaron a IPS de Tunja durante el año 2004. Materiales y Métodos Estudio de corte transversal, la información se recogió mediante aplicación de una encuesta a 129 niños menores de 5 años afectados de EDA. Adicionalmente se recogió una muestra de heces, en las consultas externas del Hospital San Rafael y Clínica Saludcoop de Tunja. Resultados Se encontró Rotavirus en 48,1 por ciento, Shigella 0,8 por ciento, E. coli 13,9 por ciento; Campylobacter 2,3 por ciento; Giardia lamblia 12,4 por ciento; E. histolytica 7 por ciento; en 15,5 por ciento de casos no se identificó agente causal. La asociación es creciente con la edad para Rotavirus (p<0,01), E.Coli (p<0,05) y Campylobacter (p<0,001). Conclusión Rotavirus es el mayor agente causal de EDA en menores de 1 año, y en general, en menores de 5 años. Las prevalencias encontradas coinciden con lo reportado en estudios realizados en Facatativá, Bogotá, Santander, Manizales y Chocó; también con estudios adelantados en Venezuela, Perú y México.

Objectives: Determining the prevalence and type of infectious ADD-causing agents in a sample of children aged less than five who consulted the IPS in Tunja during 2004. Material and Methods A cross-sectional study was designed. Data was obtained by surveying 129 children younger than 5 suffering from ADD. Samples of faeces were obtained following outpatient consultation at San Rafael Hospital and SaludCoopÆs clinic in Tunja. Results Rotavirus was found in 48,1 percent of cases, Shigella in 0,8 percent, E. coli in 13,9 percent, Campylobacter in 2,3 percent, Giardia lamblia in 12,4 percent and E. hitolytica in 7 percent. The causative agent could not be identified in 15,5 percent of cases. The statistical association grew with age for Rotavirus (p<0.01), E. coli (p<0.05) and campylobacter (p<0.001). Conclusion Rotavirus is the major causative agent of ADD in children younger than one year and, generally, in children aged less than five. The prevalence found was similar to data reported in studies carried out in Facatatativá, Bogotá, Santander, Manizales and the Chocó in Colombia and studies carried out in Venezuela, Peru and Mexico.

Highly purified human-derived follicle-stimulating hormone (Bravelle) has equivalent efficacy to follitropin-beta (Follistim) in infertile women undergoing in vitro fertilization.

BACKGROUND: These data compare the efficacy and safety of highly purified human-derived follicle-stimulating hormone (Bravelle) and recombinant follitropin-beta (Follistim) in women undergoing in vitro fertilization. METHODS: This report describes the pooled data from two, nearly identical, randomized, controlled, parallel-group, multicenter studies conducted in a total of 19 academic and private IVF-ET centers in the United States. Infertile premenopausal women underwent pituitary down-regulation using leuprolide acetate followed by a maximum of 12 days of subcutaneous Bravelle (n = 120) or Follistim (n = 118), followed by administration of human chorionic gonadotropin, oocyte retrieval and embryo transfer. The primary efficacy measure was the mean number of oocytes retrieved; secondary efficacy measures included the total dose and duration of gonadotropin treatment; peak serum estradion levels; embryo transfer and implantation rates; chemical, clinical and continuing pregnancies; and live birth rates. All adverse events were recorded and injection site pain was recorded daily using a patient, self-assessment diary. RESULTS: Similar efficacy responses were observed for all outcome parameters in the two treatment groups. Although patients receiving Bravelle consistently reported a greater number of chemical, clinical and continuing pregnancies, as well as an increased rate of live birth, the data did not attain statistical significance (P > 0.05). The overall incidence of adverse events was similar in both groups, but compared to Follistim, injections of Bravelle were reported by patients to be significantly less painful (P < 0.001). CONCLUSIONS: Bravelle and Follistim had comparable efficacy in controlled ovarian hyperstimulation in women undergoing IVF-ET. There were no differences in the nature or number of adverse events between the treatment groups although Bravelle injections were reported to be significantly less painful.

Sequential hormonal supplementation with vaginal estradiol and progesterone gel corrects the effect of clomiphene on the endometrium in oligo-ovulatory women.

BACKGROUND: We investigated the possibility of correcting the endometrial alterations induced with clomiphene citrate (CC) by vaginal hormonal supplementation (HS) with estradiol (E2) and progesterone gel. METHODS: Oligo-ovulatory women were prospectively randomized into four groups receiving either 50 mg (groups 1 and 2) or 100 mg (groups 3 and 4) of CC from cycle day 3-8. Groups 2 and 4 also received vaginal E2 cream 0.1 mg twice daily from day 8 until the LH surge and vaginal progesterone gel, starting 3 days after ovulation. All participants had an endometrial biopsy performed 10 +/- 1 days after ovulation. RESULTS: All biopsies in the HS groups (2 and 4) showed complete predecidual changes, and were 'in-phase' with findings normally made 10 days post-ovulation (+/- 2 days of clinical dating). However, without HS (groups 1 and 3), only 4/6 and 3/6 biopsies showed predecidual changes in women receiving 50 and 100 mg of CC. CONCLUSION: The addition of vaginal E2 and progesterone to CC ovulation induction regimens normalizes the alterations in endometrial morphology. Hormonal treatment combining vaginal E2 and progesterone may improve endometrial receptivity in CC cycles and ultimately yield higher pregnancy rates.